Comparing NewGenIvf Group (NASDAQ:NIVF) & Medpace (NASDAQ:MEDP)

NewGenIvf Group (NASDAQ:NIVF) and Medpace (NASDAQ:MEDP) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their risk, institutional ownership, analyst recommendations, earnings, dividends, valuation and profitability.

Valuation and Earnings

This table compares NewGenIvf Group and Medpace”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
NewGenIvf Group	$5.43 million	0.12	-$520,000.00	N/A	N/A
Medpace	$2.53 billion	5.23	$451.12 million	$15.30	30.45

Medpace has higher revenue and earnings than NewGenIvf Group.

Profitability

This table compares NewGenIvf Group and Medpace’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
NewGenIvf Group	N/A	N/A	N/A
Medpace	17.83%	118.82%	25.07%

Insider & Institutional Ownership

66.2% of NewGenIvf Group shares are owned by institutional investors. Comparatively, 78.0% of Medpace shares are owned by institutional investors. 31.8% of NewGenIvf Group shares are owned by company insiders. Comparatively, 20.3% of Medpace shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Risk and Volatility

NewGenIvf Group has a beta of 0.01, suggesting that its share price is 99% less volatile than the S&P 500. Comparatively, Medpace has a beta of 1.44, suggesting that its share price is 44% more volatile than the S&P 500.

Analyst Ratings

This is a breakdown of recent ratings and recommmendations for NewGenIvf Group and Medpace, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
NewGenIvf Group	1	0	0	0	1.00
Medpace	2	8	5	0	2.20

Medpace has a consensus price target of $486.67, suggesting a potential upside of 4.47%. Given Medpace’s stronger consensus rating and higher probable upside, analysts clearly believe Medpace is more favorable than NewGenIvf Group.

Summary

Medpace beats NewGenIvf Group on 11 of the 12 factors compared between the two stocks.

About NewGenIvf Group

NewGenIVF Group Ltd. operates as an assisted reproductive services provider. It focuses on providing fertility treatments to fulfil the dreams of building families. The firm offers in-vitro fertilization treatment service, comprising traditional IVF and egg donation, and surrogacy and ancillary caring services. The company was founded by Siu Wing Fung and Fong Hei Yue on January 16, 2019 and is headquartered in Bangkok, Thailand.

About Medpace

Medpace Holdings, Inc. engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance. The company was founded by August James Troendle in 1992 and is headquartered in Cincinnati, OH.